Floatz logo

Capecitabine

Thromboembolism

Odense University HospitalSmall moleculeDormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Thromboembolism cohort.

Asset / SponsorPhaseRating
NADROPARIN
Rijnstate Hospital
Phase 4BBB
Fragmin
Beijing Friendship Hospital
Phase 4BBB
FONDAPARINUX
University of Alabama at Birmingham
Phase 2BB
Tinzaparin
University College Dublin
Phase 3BB
WARFARIN
Hamilton Health Sciences Corporation
Phase 2B

View all 11 →

Same molecule, other indications

Capecitabine is also rated in:

Locally Advanced Rectal CancerDormant
BBB
Indicative ·
75 / 100
View asset →
colorectal neoplasmDormant
BBB
Indicative ·
74 / 100
View asset →
rectal carcinomaDormant
BBB
Indicative ·
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →